Assembly Biosciences vs Viridian Therapeutics
Assembly Biosciences reported revenue of $72 million in fiscal 2025, about the same as Viridian Therapeutics' $71 million in fiscal 2025. Assembly Biosciences' revenue grew 153.5% in its latest year, and Viridian Therapeutics' grew 23359.9%. Assembly Biosciences had an operating margin of -16.8%, against -512.9% at Viridian Therapeutics. Free cash flow was −$41 million at Assembly Biosciences and −$277 million at Viridian Therapeutics.
Side by side
| Assembly Biosciences | Viridian Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $72M | $71M |
| Revenue growth | 153.5% | 23,359.9% |
| Revenue growth a year, last 5 years | −1.8% | 130.0% |
| Gross margin | — | — |
| Operating margin | −16.8% | −512.9% |
| Net margin | −8.5% | −483.6% |
| Free cash flow | −$41M | −$277M |
| Free cash flow margin | −56.9% | −390.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 86.7% | — |
| Last close | $22.50 | $31.44 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $14,687 | bought $20.0 million, sold $418,990 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Assembly BiosciencesViridian Therapeutics
Operating margin
Percent of revenue
Assembly BiosciencesViridian Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Assembly BiosciencesViridian Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Assembly Biosciences and Viridian Therapeutics pages.